WuXi AppTec Shares Rally Amid Sectorwide Gains After Tech Selloff, China Policy Support
By Jason Chau
Shares of Chinese biopharmaceutical company WuXi AppTec surged Wednesday as investors turned to healthcare stocks amid a global tech selloff and were encouraged by fresh policy support from Beijing.
WuXi AppTec's shares in Hong Kong rose as much as 11% before paring some gains to close 8.3% higher, while its Shanghai-listed stock surged as much as 10% before ending the day 8.6% higher.
WuXi Biologics and WuXi XDC rose 8.9% and 4.2%, respectively. Peers BeOne Medicines and Innovent Biologics advanced 2.7% and 1.5%, respectively, in Hong Kong.
Sharp swings in tech stocks this week have prompted some traders to "fly to safety" in healthcare, a heavily sold sector with strong fundamentals, said Nomura China healthcare analyst Jialin Zhang.
Meanwhile, Beijing's measures aimed at encouraging foreign investment in the pharmaceutical sector, announced Tuesday, signal continued commitment from Chinese authorities to opening up the sector to foreign capital, said Citi analysts in a note.
The measures, jointly issued by China's commerce and finance ministries and the National Development and Reform Commission, include broader commercial insurance coverage for innovative drugs and expanded retail sales channels for foreign medicines.
Optimism was further boosted by U.S. pharma giant Eli Lilly's new research and development partnership with Chinese biotech company Abbisko, Nomura's Zhang added. The deal could be worth as much as $1.9 billion.
WuXi-named companies posted the strongest gains in the healthcare sector, partly supported by recent share buyback plans that reflect managements' confidence in the businesses, Citi said.
Sentiment toward Chinese drugmakers has been strong since last year following a flurry of partnerships between Chinese biotech companies and global pharma names.
"China's innovative drug pipeline is advancing at a global leading speed and cost," Citi said, adding that it sees "high management confidence and strong operational momentum across the value chain."
Write to Jason Chau at jason.chau@wsj.com
(END) Dow Jones Newswires
June 24, 2026 06:04 ET (10:04 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
September Stock Market Outlook: How to Position Your Portfolio During a Risky Stage
3 Stocks to Sell and 3 Stocks to Buy for September
Worried About a Stock Market Bubble? Here Are 5 Ways to Stay Invested
TIPS Look Tempting. Should You Buy?
United States